The execs at Haleon, a huge multinational consumer products company, ought to take a good look in the mirror. That is, unless ...

The weight-loss drug is on track to log over $13 billion in global sales in 2025, according to Evaluate, a pharmaceutical intelligence ... from a Chinese company. GSK acquired Aiolos months ...

The new money means that iTeos can now fund its activities through 2027, including the start of multiple phase 3 studies of belrestotug in combination with GSK’s PD-1 inhibitor Jemperli ...

Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts. The Put/Call ...

The logo of British pharmaceutical giant GlaxoSmithKline (GSK) is pictured at the company's offices in Munich. Sven Hoppe/dpa Annual core operating profit increased in 2024 for British ...

GSK's Q4 EPS and sales beat estimates Shares jump 6% R&D investment to focus on speciality medicines Feb 5 (Reuters) - GSK (GSK.L), opens new tab launched a 2 billion pounds ($2.5 billion) share ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long ... with 90% of the total coming from products that are already approved or planned for ...

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...